MedPath

Raltegravir

Generic Name
Raltegravir
Brand Names
Isentress
Drug Type
Small Molecule
Chemical Formula
C20H21FN6O5
CAS Number
518048-05-0
Unique Ingredient Identifier
22VKV8053U
Background

Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S. Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval.

Indication

For the treatment of HIV-1 infection in conjunction with other antiretrovirals.

Associated Conditions
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Associated Therapies
Post-exposure prophylaxis for occupational exposure to HIV therapy
Clinical Trials
Related News

Pilot Study of Adding Raltegravir (MK-0518) to Antiretroviral Therapy in Patients With Low Level Viremia

Not Applicable
Completed
Conditions
HIV Infection
Interventions
First Posted Date
2008-02-20
Last Posted Date
2017-02-01
Lead Sponsor
University of Pittsburgh
Target Recruit Count
10
Registration Number
NCT00618371
Locations
🇺🇸

University of Pittsburgh, Pittsburgh, Pennsylvania, United States

Pharmacokinetic Study on Raltegravir and Lamotrigine

Phase 1
Completed
Conditions
HIV Infection
Interventions
First Posted Date
2008-02-19
Last Posted Date
2020-10-19
Lead Sponsor
Radboud University Medical Center
Target Recruit Count
24
Registration Number
NCT00618241
Locations
🇳🇱

Radboud University Medical Center, Nijmegen, Gelderland, Netherlands

An Interaction Study to Assess Drug Levels in Healthy Adult Subjects

Not Applicable
Completed
Conditions
Healthy
Interventions
First Posted Date
2008-02-14
Last Posted Date
2016-01-29
Lead Sponsor
Garden State Infectious Disease Associates, PA
Target Recruit Count
44
Registration Number
NCT00614991

Raltegravir Added to Stable HAART in HIV-1 Infected Subjects With Viral Suppression and Low CD4 Recovery

Phase 3
Terminated
Conditions
HIV Infections
Interventions
Drug: Placebo
First Posted Date
2007-11-22
Last Posted Date
2015-06-09
Lead Sponsor
Pedro Cahn
Target Recruit Count
20
Registration Number
NCT00562510
Locations
🇦🇷

Fundacion Huesped, Buenos Aires, Argentina

Characterization of Acute and Recent HIV-1 Infections in Zurich.

Not Applicable
Recruiting
Conditions
HIV Infections
Interventions
Drug: Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamid Fumarate
First Posted Date
2007-10-02
Last Posted Date
2024-12-17
Lead Sponsor
University of Zurich
Target Recruit Count
800
Registration Number
NCT00537966
Locations
🇨🇭

University of Zurich, Zurich, Switzerland

Optimizing Treatment for Treatment-Experienced, HIV-Infected People

First Posted Date
2007-10-01
Last Posted Date
2021-11-04
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
517
Registration Number
NCT00537394
Locations
🇺🇸

Children's National Med. Ctr. ATN CRS, Washington, District of Columbia, United States

🇺🇸

Univ. of Rochester ACTG CRS, Rochester, New York, United States

🇺🇸

UCLA CARE Center CRS, Los Angeles, California, United States

and more 61 locations

Raltegravir Insulin Sensitivity Study

First Posted Date
2007-09-19
Last Posted Date
2010-08-16
Lead Sponsor
St Stephens Aids Trust
Target Recruit Count
18
Registration Number
NCT00531999
Locations
🇬🇧

St Stephens Centre, Chelsea & Westminster Hospital, London, United Kingdom

Evaluating the Effect of CHanging EnfuvirtidE to Raltegravir in HIV Infected Subjects

Phase 3
Completed
Conditions
HIV Infections
Interventions
First Posted Date
2007-09-14
Last Posted Date
2018-08-07
Lead Sponsor
Kaiser Permanente
Target Recruit Count
52
Registration Number
NCT00529243
Locations
🇺🇸

Kaiser Hayward, Hayward, California, United States

🇺🇸

Kaiser Anaheim, Anaheim, California, United States

🇺🇸

Kaiser Panorama City, Panorama City, California, United States

and more 5 locations

Switching From PI to RALtegravir in HIV Stable Patients

Phase 3
Completed
Conditions
HIV Infections
Interventions
Drug: boosted PI
First Posted Date
2007-09-12
Last Posted Date
2010-03-31
Lead Sponsor
Hospital Clinic of Barcelona
Target Recruit Count
282
Registration Number
NCT00528892
Locations
🇪🇸

Hospital Clinic, Barcelona, Spain

Standard Antiretroviral v. Multi-class Therapy in Acutely HIV-1 Infected Antiretroviral-Naïve Subjects (ADARC 2007-01)

Not Applicable
Completed
Conditions
HIV Infections
Interventions
Drug: FTC 200 mg/TDF 300mg
First Posted Date
2007-09-06
Last Posted Date
2015-03-09
Lead Sponsor
Rockefeller University
Target Recruit Count
40
Registration Number
NCT00525733
Locations
🇺🇸

Rockefeller University, New York, New York, United States

🇺🇸

The Rockefeller University, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy